Moonasar Rampertaap, MD
Pulmonary Disease · Bradenton, FLNPI 1558439083
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $78,943 of the $109,167 with a category attached, or 72.3%. 30 manufacturers reported payments, led by United Therapeutics Corporation at 53.6% of the total. Reporting peaked in 2019 at $61,331 and has fallen 98.0% since, to $1,199 in 2025. Among pulmonary disease clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 628 payments — averaging $173.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- United Therapeutics Corporation$59K
- Boehringer Ingelheim$33K
- Actelion Pharmaceuticals US, Inc.$9K
- GSK$2K
- Takeda Pharmaceuticals U.S.A., Inc.$2K
- AstraZeneca$1K
- plus $5K from 24 others
Across 7 payments — averaging $2823.71 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sanofi US Services Inc.$11K
- United Therapeutics Corporation$9K
What the payments were for
- Consulting fees$12,05611%
- Speaking & faculty fees$78,94372%
- Grants$1,0001%
- Travel & lodging$2,3872%
- Food & beverage$14,57013%
- Education$2110%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| United Therapeutics Corporation | 90 | $58,534 |
| Boehringer Ingelheim | 109 | $32,690 |
| Actelion Pharmaceuticals US, Inc. | 79 | $8,694 |
| GSK | 101 | $1,767 |
| Takeda Pharmaceuticals U.S.A., Inc. | 73 | $1,650 |
| AstraZeneca | 30 | $1,250 |
| Genentech, Inc. | 1 | $1,000 |
| Grifols USA, LLC | 32 | $674 |
| Inspire Medical Systems, Inc. | 4 | $504 |
| Genentech USA, Inc. | 16 | $303 |
| Regeneron Healthcare Solutions, Inc. | 7 | $273 |
| Mylan Specialty L.p. | 14 | $273 |
| Bayer | 13 | $202 |
| Insmed, Inc. | 7 | $193 |
| Paratek Pharmaceuticals, Inc. | 8 | $171 |
| Jazz Pharmaceuticals Inc. | 9 | $163 |
| Harmony Biosciences LLC | 7 | $161 |
| Vanda Pharmaceuticals Inc. | 5 | $113 |
| Amgen | 1 | $108 |
| Sanofi | 5 | $102 |
| Merck | 4 | $72 |
| Gilead | 3 | $62 |
| Philips North America LLC | 2 | $61 |
| CSL Behring | 2 | $31 |
| Vapotherm Inc | 1 | $23 |
| Johnson & Johnson | 1 | $23 |
| Verona Pharma, Inc. | 1 | $19 |
| Baxter Healthcare | 1 | $19 |
| Nabriva Therapeutics, PLC | 1 | $17 |
| Resmed Corp | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$109,167 in reported general payments places this provider in the 95th percentile of 953 pulmonary disease providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 687 | $620,235 |
| UptraviSelexipag | 24 | $548,046 |
| OfevNintedanib Esylate | 33 | $428,123 |
| OpsumitMacitentan | 23 | $286,880 |
| Orenitram ErTreprostinil Diolamine | 36 | $238,779 |
| GlassiaAlpha-1-Proteinase Inhibitor | 20 | $208,964 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 124 | $107,936 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 108 | $82,218 |
| Spiriva RespimatTiotropium Bromide | 36 | $29,763 |
| Wixela InhubFluticasone Propion/Salmeterol | 94 | $23,105 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 126 | $21,133 |
| Breo ElliptaFluticasone/Vilanterol | 31 | $19,885 |
| Pirfenidone | 11 | $15,845 |
| Advair HfaFluticasone Propion/Salmeterol | 17 | $11,472 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 355 | $9,686 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Actelion Pharmaceuticals US, Inc.Uptravi, Opsumit | $8,694 | $834,92647 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $1,767 | $640,121718 claims |
| Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat | $32,690 | $540,104177 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Glassia | $1,650 | $208,96420 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $1,250 | $116,802149 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 953 pulmonary disease providers in Florida.
Other pulmonary disease in Bradenton
- John PetersBradenton$71K
- Franck RahaghiWeston$1.2M
- Michael OttEglin Afb$909K
- Ali JiwaniOrlando$859K
- Anas HadehWeston$800K
- Jennifer FultonJacksonville$665K
- Ricardo Restrepo-JaramilloTampa$555K
- Mark RumbakTampa$528K
- Jose Soto SotoJacksonville$504K
- Javier Perez FernandezMiami$496K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.